Shorter spell of endocrine therapy 'sufficient' for breast cancer
Results are strong evidence against routine extended use in postmenopausal women with hormone-receptor positive disease, expert says
Two years of extra therapy with an adjuvant aromatase inhibitor is sufficient for women with hormone-receptor-positive breast cancer, according to trial results.
The finding should change clinical practice, with women needing only a total of seven years’ endocrine therapy rather than 10, the authors say.
In the trial, dubbed ABCSG-16/SALSA, almost 3500 postmenopausal volunteers from 75 Austrian cancer clinics had already received
